Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Moderna, Inc. - Common Stock (NQ:MRNA)

26.89 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Via ACCESS Newswire
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
Via ACCESS Newswire
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Via ACCESS Newswire
Moderna Announces Data to be Presented at ESMO Congress 2025
Via ACCESS Newswire
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
Via ACCESS Newswire
Moderna Announces Update on Investigational Pandemic Influenza Program
Via ACCESS Newswire
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
Via ACCESS Newswire
Moderna to Present at Upcoming Conferences in March 2025
Via ACCESS Newswire
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Via ACCESS Newswire
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
Via ACCESS Newswire
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Via ACCESS Newswire
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
Via ACCESS Newswire
Moderna to Present at Upcoming Conferences in June 2025
Via ACCESS Newswire
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
Via ACCESS Newswire
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
Moderna to Present at Upcoming Conferences in December 2024
Via ACCESSWIRE
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
Via ACCESSWIRE
Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
Via ACCESS Newswire
Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
Via ACCESS Newswire
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Via ACCESS Newswire
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Via ACCESS Newswire
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Via ACCESSWIRE
Moderna to Present at Upcoming Conferences in November 2024
Via ACCESSWIRE
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
Via ACCESS Newswire
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
Via ACCESS Newswire
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Via ACCESS Newswire
Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025
Via ACCESS Newswire
Moderna Announces Updates on Pandemic Influenza Program
Via ACCESS Newswire
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.